RU2018103235A - Оптимально активированные дендритные клетки, индуцирующие улучшенный или повышенный противоопухолевый иммунный ответ - Google Patents
Оптимально активированные дендритные клетки, индуцирующие улучшенный или повышенный противоопухолевый иммунный ответ Download PDFInfo
- Publication number
- RU2018103235A RU2018103235A RU2018103235A RU2018103235A RU2018103235A RU 2018103235 A RU2018103235 A RU 2018103235A RU 2018103235 A RU2018103235 A RU 2018103235A RU 2018103235 A RU2018103235 A RU 2018103235A RU 2018103235 A RU2018103235 A RU 2018103235A
- Authority
- RU
- Russia
- Prior art keywords
- dendritic cells
- tumor
- cells
- human dendritic
- bcg
- Prior art date
Links
- 230000001939 inductive effect Effects 0.000 title claims 9
- 230000005975 antitumor immune response Effects 0.000 title claims 2
- 210000004443 dendritic cell Anatomy 0.000 claims 36
- 238000000034 method Methods 0.000 claims 16
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 239000002243 precursor Substances 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 10
- 230000035800 maturation Effects 0.000 claims 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- -1 imidazoquinoline compound Chemical class 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000003104 tissue culture media Substances 0.000 claims 4
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 238000002955 isolation Methods 0.000 claims 3
- FQYRLEXKXQRZDH-UHFFFAOYSA-N 4-aminoquinoline Chemical compound C1=CC=C2C(N)=CC=NC2=C1 FQYRLEXKXQRZDH-UHFFFAOYSA-N 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 2
- 102000004889 Interleukin-6 Human genes 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 102000004890 Interleukin-8 Human genes 0.000 claims 2
- 108090001007 Interleukin-8 Proteins 0.000 claims 2
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 230000004069 differentiation Effects 0.000 claims 2
- 239000002158 endotoxin Substances 0.000 claims 2
- 229940124669 imidazoquinoline Drugs 0.000 claims 2
- 229940100601 interleukin-6 Drugs 0.000 claims 2
- 229940096397 interleukin-8 Drugs 0.000 claims 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 claims 2
- 229920006008 lipopolysaccharide Polymers 0.000 claims 2
- 210000001165 lymph node Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 210000005259 peripheral blood Anatomy 0.000 claims 2
- 239000011886 peripheral blood Substances 0.000 claims 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 239000003970 toll like receptor agonist Substances 0.000 claims 2
- 238000005406 washing Methods 0.000 claims 2
- 241000193830 Bacillus <bacterium> Species 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 102000003816 Interleukin-13 Human genes 0.000 claims 1
- 108090000176 Interleukin-13 Proteins 0.000 claims 1
- 102000003812 Interleukin-15 Human genes 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- 102000004388 Interleukin-4 Human genes 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 102000000704 Interleukin-7 Human genes 0.000 claims 1
- 108010002586 Interleukin-7 Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 102000002689 Toll-like receptor Human genes 0.000 claims 1
- 108020000411 Toll-like receptor Proteins 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 230000024245 cell differentiation Effects 0.000 claims 1
- 210000002421 cell wall Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000004041 dendritic cell maturation Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000004700 fetal blood Anatomy 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000028709 inflammatory response Effects 0.000 claims 1
- 229960003130 interferon gamma Drugs 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 238000002271 resection Methods 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 210000001541 thymus gland Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
- C12N5/064—Immunosuppressive dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/35—Cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/72—Undefined extracts from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/05—Adjuvants
- C12N2501/052—Lipopolysaccharides [LPS]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2304—Interleukin-4 (IL-4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2313—Interleukin-13 (IL-13)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562187086P | 2015-06-30 | 2015-06-30 | |
| US62/187,086 | 2015-06-30 | ||
| PCT/US2016/040134 WO2017004230A1 (en) | 2015-06-30 | 2016-06-29 | Optimally activated dendritic cells that induce an improved or increased anti-tumor immune response |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2018103235A true RU2018103235A (ru) | 2019-07-31 |
| RU2018103235A3 RU2018103235A3 (enExample) | 2019-12-23 |
Family
ID=57609106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018103235A RU2018103235A (ru) | 2015-06-30 | 2016-06-29 | Оптимально активированные дендритные клетки, индуцирующие улучшенный или повышенный противоопухолевый иммунный ответ |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11124768B2 (enExample) |
| EP (2) | EP3317403B1 (enExample) |
| JP (3) | JP6985939B2 (enExample) |
| KR (1) | KR102763373B1 (enExample) |
| CN (2) | CN114774356A (enExample) |
| AR (1) | AR106496A1 (enExample) |
| AU (2) | AU2016286112B2 (enExample) |
| CA (1) | CA2990640A1 (enExample) |
| ES (1) | ES3032055T3 (enExample) |
| IL (2) | IL312668A (enExample) |
| MX (2) | MX2018000056A (enExample) |
| PL (1) | PL424035A1 (enExample) |
| RU (1) | RU2018103235A (enExample) |
| WO (1) | WO2017004230A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018160666A1 (en) * | 2017-02-28 | 2018-09-07 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Short-term activated dc1s and methods for their production and use |
| CA3157004A1 (en) * | 2019-10-07 | 2021-04-15 | Northwest Biotherapeutics, Inc. | In vitro methods and compositions for enhancing the activation of dendritic cells and t cells, and for inducing a th-1 immune response |
| CN117417886B (zh) * | 2023-10-20 | 2024-05-14 | 广东壹加再生医学研究院有限公司 | 一种负载肿瘤抗原的树突状细胞激活的t淋巴细胞的培养方法 |
| CN119286782B (zh) * | 2024-12-11 | 2025-04-04 | 上海赛笠百傲生物医药有限公司 | 一种高效诱导外周血来源单核细胞至不成熟树突状细胞的方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0633929T3 (da) | 1992-04-01 | 2004-06-28 | Univ Rockefeller | Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener |
| US6080409A (en) * | 1995-12-28 | 2000-06-27 | Dendreon Corporation | Immunostimulatory method |
| US7659119B2 (en) | 1996-02-12 | 2010-02-09 | Argos Therapeutics, Inc. | Method and compositions for obtaining mature dendritic cells |
| US6558951B1 (en) | 1999-02-11 | 2003-05-06 | 3M Innovative Properties Company | Maturation of dendritic cells with immune response modifying compounds |
| US20020094545A1 (en) | 2000-11-30 | 2002-07-18 | Harris Paul E. | Growth of human dendritic cells for cancer immunotherapy in closed system using microcarrier beads |
| WO2003010292A2 (en) | 2001-07-25 | 2003-02-06 | Northwest Biotherapeutics, Inc. | Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors |
| EP2322603B1 (en) * | 2001-09-06 | 2019-10-16 | NorthWest Biotherapeutics, Inc. | Compositions and methods for priming monocytic dendritic cells and T cells for Th1 response |
| HUE031517T2 (en) | 2002-06-19 | 2017-07-28 | Northwest Biotherapeutics Inc | Cross-flow filtration equipment and procedures for leukocyte enrichment |
| WO2004053072A2 (en) * | 2002-12-06 | 2004-06-24 | Northwest Biotherapeutics, Inc. | Administration of dendritic cells partially matured in vitro for the treatment of tumors |
| DK1604016T3 (da) * | 2003-02-27 | 2009-05-18 | Northwest Biotherapeutics Inc | In vitro-fremgangsmåde til differentiering af monocytiske dendritiske precursorceller i umodne dendritiske celler |
| KR100887560B1 (ko) | 2007-04-24 | 2009-03-09 | 크레아젠 주식회사 | 준성숙 수지상 세포를 포함하는 류마티스 관절염 치료용약제학적 조성물 |
| EP3375868A1 (en) * | 2007-11-08 | 2018-09-19 | Dana Farber Cancer Institute, Inc. | Stimulation of anti-tumor immunity using dendritic cell/tumor cell fusions and anti-cd3/cd28 |
| EP2072617A1 (en) | 2007-12-12 | 2009-06-24 | Trimed Biotech GmbH | Method for producing dendritic cells |
| ES2686708T3 (es) | 2008-04-18 | 2018-10-19 | Baxter International Inc. | Composición basada en microesferas para prevenir y/o revertir la diabetes autoinmune de nueva aparición |
| US10238723B2 (en) * | 2013-03-14 | 2019-03-26 | Icahn School Of Medicine At Mount Sinai | Autologous tumor lysate-loaded dendritic cell vaccine for treatment of liver cancer |
-
2016
- 2016-06-29 CN CN202210272735.4A patent/CN114774356A/zh active Pending
- 2016-06-29 KR KR1020187002974A patent/KR102763373B1/ko active Active
- 2016-06-29 WO PCT/US2016/040134 patent/WO2017004230A1/en not_active Ceased
- 2016-06-29 EP EP16818706.0A patent/EP3317403B1/en active Active
- 2016-06-29 US US15/740,094 patent/US11124768B2/en active Active
- 2016-06-29 AU AU2016286112A patent/AU2016286112B2/en active Active
- 2016-06-29 JP JP2017567686A patent/JP6985939B2/ja active Active
- 2016-06-29 CA CA2990640A patent/CA2990640A1/en active Pending
- 2016-06-29 IL IL312668A patent/IL312668A/en unknown
- 2016-06-29 MX MX2018000056A patent/MX2018000056A/es unknown
- 2016-06-29 IL IL256522A patent/IL256522B2/en unknown
- 2016-06-29 PL PL424035A patent/PL424035A1/pl unknown
- 2016-06-29 CN CN201680038886.6A patent/CN107849537A/zh active Pending
- 2016-06-29 EP EP25161616.5A patent/EP4574159A3/en active Pending
- 2016-06-29 RU RU2018103235A patent/RU2018103235A/ru not_active Application Discontinuation
- 2016-06-29 ES ES16818706T patent/ES3032055T3/es active Active
- 2016-06-30 AR ARP160101986A patent/AR106496A1/es unknown
-
2018
- 2018-01-08 MX MX2023001622A patent/MX2023001622A/es unknown
-
2021
- 2021-09-17 US US17/477,949 patent/US20220145246A1/en active Pending
- 2021-11-26 JP JP2021191885A patent/JP2022023248A/ja not_active Withdrawn
-
2023
- 2023-05-12 AU AU2023202977A patent/AU2023202977A1/en active Pending
-
2024
- 2024-06-03 JP JP2024089927A patent/JP2024101059A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2005121256A (ru) | Введение дендритных клеток, подвергнутых частичному созреванию in vitro, для лечения опухолей | |
| EP2494038B1 (en) | Method for proliferation of antigen-specific t cells | |
| RU2766457C2 (ru) | Способы и композиции для лечения рака с помощью антисмысла | |
| Sloan et al. | Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony–stimulating factor and adoptive transfer of anti-CD3–activated lymphocytes | |
| RU2018103235A (ru) | Оптимально активированные дендритные клетки, индуцирующие улучшенный или повышенный противоопухолевый иммунный ответ | |
| US9034317B2 (en) | Composition for inhibiting tumor cell proliferation | |
| JP2024019229A (ja) | 進行したがんを有する被験体のための活性化樹状細胞組成物および免疫療法処置に関する方法 | |
| JP2018523996A5 (enExample) | ||
| JP2018537949A5 (enExample) | ||
| KR20220098351A (ko) | 수지상 세포 및 T 세포의 활성화를 증진시키고 Th-1 면역 반응을 유도하기 위한 시험관내 방법 및 조성물 | |
| Du et al. | Fusion of CpG‐ODN‐stimulating dendritic cells with Lewis lung cancer cells can enhance anti‐tumor immune responses | |
| CN104630145A (zh) | 一种抗肿瘤t细胞、其制备方法和抗肿瘤药物 | |
| O'Neill et al. | Immunotherapeutic potential of dendritic cells generated in long term stroma-dependent cultures | |
| Sonmez et al. | The role of hepatocyte growth factor in the differentiation of dendritic cells from peripheral blood monocytes | |
| WO2001062092A1 (en) | Formulations and methods for using the same to elicit an immune response | |
| HK40085184A (en) | In vitro methods and compositions for enhancing the activation of dendritic cells and t cells, and for inducing a th-1 immune response | |
| JPWO2021071977A5 (enExample) | ||
| CZ22766U1 (cs) | Sada pro přípravu protínádorové vakcíny a protinádorová vakcína |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20220411 |